KS370G
Based on 1 Customer Validation
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 105955-01-9
- Formula: C17H17NO3
- Molecular Weight:283.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Aging Compound Library
HY-L034
-
Covalent Screening Library
HY-L036
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Cysteine Targeted Covalent Library
HY-L153
-
Cysteine Targeted Covalent Fragment Library
HY-L154
-
Bioactive Compound Library Max
HY-L181
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HUVEC | EC50 |
2 μM
Compound: 4a, CAPA
|
Cytoprotective activity against H2O2-induced oxidative stress in HUVEC cells after 18 hrs by Cell-Titer Blue assay
Cytoprotective activity against H2O2-induced oxidative stress in HUVEC cells after 18 hrs by Cell-Titer Blue assay
|
[PMID: 20598894] |
| LNCaP | IC50 |
>100 μM
Compound: 34
|
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay
|
[PMID: 24080105] |
KS370G (10 mg/kg; oral; once daily for 13 days) attenuates unilateral ureteral obstruction-induced renal fibrosis by the reduction of inflammation and oxidative stress in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pressure-overload ICR mice model[1]
-
Dosage:1 mg/kg
-
Administration:Oral gavage, once daily for 8 weeks
-
Result:Inhibited cardiac hypertrophy and improved cardiac function induced by pressure overload. Decreased the plasma levels of atrial natriuretic peptide and lactate dehydrogenase. Significantly reduced pressure overload-induced increase of α-SMA and phosphorylation of ERK, AKT and GSK3β. Reduced cardiac collagen accumulation.
-
Animal Model:Male ICR mice, unilateral ureteral obstruction (UUO) model[2]
-
Dosage:10 mg/kg
-
Administration:Oral, once daily for 13 days
-
Result:Significantly attenuated collagen deposition in the obstructed kidney and inhibited UUO-induced renal fibrosis markers expression, including fibronectin, type I collagen, vimentin, and α-smooth muscle actin (α-SMA). Significantly lowered the expression of renal inflammatory chemokines/adhesion molecules and monocyte cells marker (MCP-1, VCAM-1, ICAM-1 and CD11b). Reduced renal malondialdehyde levels and reversed the expression of renal antioxidant enzymes (SOD and catalase) after UUO. Significantly inhibited UUOinduced elevated plasma AngII and TGF-β1 levels, TGF-β1 protein expression and Smad3 phosphorylation.
Chemical Information
-
CAS No. 105955-01-9
-
Appearance Solid
-
Molecular Weight 283.32
-
Formula C17H17NO3
-
Color White to off-white
-
SMILES
O=C(/C=C/C1=CC=C(C(O)=C1)O)NCCC2=CC=CC=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (352.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chuang ST, et al. KS370G, a caffeamide derivative, attenuates unilateral ureteral obstruction-induced renal fibrosis by the reduction of inflammation and oxidative stress in mice. Eur J Pharmacol. 2015 Mar 5;750:1-7. [Content Brief]
[2]. Weng YC, et al. KS370G, a synthetic caffeamide derivative, improves left ventricular hypertrophy and function in pressure-overload mice heart. Eur J Pharmacol. 2012 Jun 5;684(1-3):108-15. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5296 mL | 17.6479 mL | 35.2958 mL | 88.2394 mL |
| 5 mM | 0.7059 mL | 3.5296 mL | 7.0592 mL | 17.6479 mL | |
| 10 mM | 0.3530 mL | 1.7648 mL | 3.5296 mL | 8.8239 mL | |
| 15 mM | 0.2353 mL | 1.1765 mL | 2.3531 mL | 5.8826 mL | |
| 20 mM | 0.1765 mL | 0.8824 mL | 1.7648 mL | 4.4120 mL | |
| 25 mM | 0.1412 mL | 0.7059 mL | 1.4118 mL | 3.5296 mL | |
| 30 mM | 0.1177 mL | 0.5883 mL | 1.1765 mL | 2.9413 mL | |
| 40 mM | 0.0882 mL | 0.4412 mL | 0.8824 mL | 2.2060 mL | |
| 50 mM | 0.0706 mL | 0.3530 mL | 0.7059 mL | 1.7648 mL | |
| 60 mM | 0.0588 mL | 0.2941 mL | 0.5883 mL | 1.4707 mL | |
| 80 mM | 0.0441 mL | 0.2206 mL | 0.4412 mL | 1.1030 mL | |
| 100 mM | 0.0353 mL | 0.1765 mL | 0.3530 mL | 0.8824 mL |
KS370G Related Classifications
HY-114683 Related Classifications
Powered by Bioz